ATE406444T1 - Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung - Google Patents
Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankungInfo
- Publication number
- ATE406444T1 ATE406444T1 AT04076254T AT04076254T ATE406444T1 AT E406444 T1 ATE406444 T1 AT E406444T1 AT 04076254 T AT04076254 T AT 04076254T AT 04076254 T AT04076254 T AT 04076254T AT E406444 T1 ATE406444 T1 AT E406444T1
- Authority
- AT
- Austria
- Prior art keywords
- disease
- proteins
- directed
- alzheime
- detection
- Prior art date
Links
- 102000008763 Neurofilament Proteins Human genes 0.000 title 1
- 108010088373 Neurofilament Proteins Proteins 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000014509 gene expression Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 102000004169 proteins and genes Human genes 0.000 abstract 5
- 230000001537 neural effect Effects 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003571 Astrocytoma Diseases 0.000 abstract 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/474—Pancreatic thread protein; Reg protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5055993A | 1993-04-20 | 1993-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406444T1 true ATE406444T1 (de) | 2008-09-15 |
Family
ID=21965952
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04076254T ATE406444T1 (de) | 1993-04-20 | 1994-04-20 | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung |
| AT94915396T ATE312348T1 (de) | 1993-04-20 | 1994-04-20 | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94915396T ATE312348T1 (de) | 1993-04-20 | 1994-04-20 | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung |
Country Status (11)
| Country | Link |
|---|---|
| EP (2) | EP1564293B9 (enExample) |
| JP (2) | JP3513859B2 (enExample) |
| KR (1) | KR100392244B1 (enExample) |
| AT (2) | ATE406444T1 (enExample) |
| CA (1) | CA2161097A1 (enExample) |
| DE (2) | DE69435136D1 (enExample) |
| DK (2) | DK0697893T3 (enExample) |
| ES (2) | ES2255054T3 (enExample) |
| NZ (1) | NZ266072A (enExample) |
| PT (1) | PT1564293E (enExample) |
| WO (1) | WO1994023756A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
| US5936078A (en) * | 1995-12-12 | 1999-08-10 | Kyowa Hakko Kogyo Co., Ltd. | DNA and protein for the diagnosis and treatment of Alzheimer's disease |
| AU1110297A (en) * | 1995-12-12 | 1997-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Novel dnas, novel polypeptides and novel antibodies |
| AU749348B2 (en) | 1997-02-26 | 2002-06-27 | General Hospital Corporation, The | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease |
| US7226730B1 (en) | 1997-02-26 | 2007-06-05 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease |
| JP2001514663A (ja) | 1997-03-12 | 2001-09-11 | エスモンド，ロバート ダブリュー． | アルツハイマー病を処置または予防するための方法 |
| EP1541166B1 (en) * | 2001-05-16 | 2007-12-19 | Nymox Corporation | Preventing cell death using segments of neural thread proteins |
| JP2004529179A (ja) | 2001-05-16 | 2004-09-24 | ナイモックス コーポレーション | 神経線維タンパク質のセグメントを使用する細胞死の予防法 |
| US6770797B2 (en) | 2001-06-01 | 2004-08-03 | Rhode Island Hospital | Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid |
| EP1714979A3 (en) * | 2001-11-16 | 2007-04-25 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| PL1994152T3 (pl) * | 2006-02-28 | 2013-05-31 | Nymox Corp | Peptydy skuteczne w leczeniu nowotworów i innych stanów wymagających usunięcia lub zniszczenia komórek |
| US20080027005A1 (en) * | 2006-07-31 | 2008-01-31 | Paul Averback | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| JP2025516554A (ja) * | 2022-05-10 | 2025-05-30 | エフ． ホフマン－ラ ロシュ アーゲー | Ｃｆｐ－ｅｌｋ１遺伝子間領域を標的とするアンチセンスオリゴヌクレオチド |
| WO2024227045A1 (en) * | 2023-04-27 | 2024-10-31 | Siemens Healthcare Diagnostics Inc. | High-sensitivity assay for serum neurofilament light chain cross reference to related applications |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0378924B1 (en) * | 1988-12-21 | 1996-11-13 | The General Hospital Corporation | Detection of neurological disease or dysfunction |
-
1994
- 1994-04-20 KR KR1019950704656A patent/KR100392244B1/ko not_active Expired - Fee Related
- 1994-04-20 AT AT04076254T patent/ATE406444T1/de not_active IP Right Cessation
- 1994-04-20 DE DE69435136T patent/DE69435136D1/de not_active Expired - Fee Related
- 1994-04-20 DK DK94915396T patent/DK0697893T3/da active
- 1994-04-20 JP JP52355694A patent/JP3513859B2/ja not_active Expired - Fee Related
- 1994-04-20 AT AT94915396T patent/ATE312348T1/de not_active IP Right Cessation
- 1994-04-20 DK DK04076254T patent/DK1564293T3/da active
- 1994-04-20 DE DE69434844T patent/DE69434844T2/de not_active Expired - Fee Related
- 1994-04-20 ES ES94915396T patent/ES2255054T3/es not_active Expired - Lifetime
- 1994-04-20 EP EP04076254A patent/EP1564293B9/en not_active Expired - Lifetime
- 1994-04-20 NZ NZ266072A patent/NZ266072A/en not_active IP Right Cessation
- 1994-04-20 WO PCT/US1994/004321 patent/WO1994023756A1/en not_active Ceased
- 1994-04-20 EP EP94915396A patent/EP0697893B1/en not_active Expired - Lifetime
- 1994-04-20 PT PT04076254T patent/PT1564293E/pt unknown
- 1994-04-20 CA CA002161097A patent/CA2161097A1/en not_active Abandoned
- 1994-04-20 ES ES04076254T patent/ES2312913T3/es not_active Expired - Lifetime
-
2003
- 2003-10-01 JP JP2003343063A patent/JP2004097227A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT1564293E (pt) | 2008-12-02 |
| EP1564293A1 (en) | 2005-08-17 |
| EP0697893B1 (en) | 2005-12-07 |
| JP3513859B2 (ja) | 2004-03-31 |
| ES2255054T3 (es) | 2006-06-16 |
| EP1564293B9 (en) | 2009-08-19 |
| EP0697893A4 (en) | 1996-12-18 |
| JP2004097227A (ja) | 2004-04-02 |
| EP0697893A1 (en) | 1996-02-28 |
| AU6666994A (en) | 1994-11-08 |
| ES2312913T3 (es) | 2009-03-01 |
| WO1994023756A1 (en) | 1994-10-27 |
| AU674581B2 (en) | 1997-01-02 |
| DE69434844D1 (de) | 2006-10-19 |
| DE69435136D1 (de) | 2008-10-09 |
| DE69434844T2 (de) | 2006-12-14 |
| DK0697893T3 (da) | 2006-02-20 |
| EP1564293B1 (en) | 2008-08-27 |
| DK1564293T3 (da) | 2009-01-12 |
| ATE312348T1 (de) | 2005-12-15 |
| JPH08509808A (ja) | 1996-10-15 |
| KR100392244B1 (ko) | 2003-11-28 |
| CA2161097A1 (en) | 1994-10-27 |
| NZ266072A (en) | 1997-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE312348T1 (de) | Geneexpression der neurofilamentproteine und nachweis der alzheimeschen erkrankung | |
| EP0442961A4 (en) | Hybrid procoagulant proteins | |
| PT939804E (pt) | Neutroquina alfa | |
| SE8106641L (sv) | Hybrida humanleukocytinterferoner | |
| DE69735375D1 (de) | Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung | |
| DE3786200D1 (de) | Diagnostische verfahren zum nachweis von lymphomen bei menschen. | |
| ATE231551T1 (de) | Huntingtin-dna, protein und verwendung | |
| DE3684295D1 (de) | Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose. | |
| ATE365744T1 (de) | Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen | |
| ATE301716T1 (de) | Vmp-ähnliche sequenzen von pathogener borrelia | |
| DE69635207D1 (de) | Auf Chromosom 1 lokalisiertes Gen dessen Genprodukt mit der Alzheimerschen Krankheit assoziiert ist. | |
| ATE354638T1 (de) | Menschlicher gewebsinhibitor von metalloproteinase-4 | |
| FI103892B1 (fi) | Rekombinantti-DNA-molekyyli, joka koodaa polypeptidiä/proteiinia, jolla on oleellisesti vaskulaaristen antikoaguloivien proteiinien biologiset ominaisuudet sekä niiden valmistus | |
| ATE380867T1 (de) | Lactoferrinrezeptorgen von moraxella | |
| ATE386800T1 (de) | Immunogene chimäre umfassend nucleinsäuresequenzen, die signalsequenzpeptide des endoplasmatischen reticulums und mindestens ein anderes peptid codieren, deren verwendung in impfstoffen und zur behandlung von krankheiten | |
| DK1015477T3 (da) | 32 humane sekreterede proteiner | |
| FI863188A0 (fi) | Kombinationsfoerfaranden foer producering av serinproteas-inhibitorer och foer dessa anvaendbara dna-sekvenser. | |
| EA199700256A1 (ru) | Выделенные последовательности днк, кодирующие капсидные белки l1 и l2 папилломавируса человека типа 18, вектор для экспресси последовательностей днк, способ получения вирусоподобных частиц и способ индуцирования иммунного ответа | |
| KR860006484A (ko) | 단백질 또는 당단백질의 제조방법 | |
| ATE187202T1 (de) | Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung | |
| AU5315790A (en) | Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes | |
| PT990000E (pt) | Factor 3 de crescimento do tecido conjuntivo | |
| NO962596L (no) | Nytt tumorsupressorgen | |
| DE69734890D1 (de) | Rdgb-proteine | |
| DE60040870D1 (de) | Das hohe knochenmasse gen auf 11q13.3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1564293 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |